Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 10, 2009, Pages 1274-1280

  Schreiber, Y S ^a   Herrera, A F ^b   Wilson, D ^c   Wallengren, K ^d   Draper, R ^c   Muller, J ^c   Dawood, H ^c   Doucette, S ^a   Cameron, D W ^a   Alvarez, Gonzalo G ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Category II regimen; Multidrug resistant tuberculosis; Outcome; Retreatment; Treatment category

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; DISEASE PREDISPOSITION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RETREATMENT; SOUTH AFRICA; TREATMENT FAILURE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETREATMENT; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 70350110237     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/publications/global-report/2008/en/index.html Accessed April 2009.
2. Murray J, Sonnenberg P, Shearer S C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740. (Pubitemid 29137767)
3. Chaisson R E, Clermont H C, Holt E A, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-1038. (Pubitemid 126679542)
4. Department of Health of South Africa. Tuberculosis strategic plan for South Africa 2007-2011. Pretoria, South Africa: Department of Health of South Africa, 2007. http://www.info.gov.za/gazette/otherdocs/2007/tbstratplan.pdf Accessed February 2009.
5. Telzak E E, Chirgwin K D, Nelson E T, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beim Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999; 3: 337-343.
6. Quy H T, Lan N T, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
7. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
8. Faustini A, Hall A J, Perucci C A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163. (Pubitemid 43235434)
9. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003. 313. Geneva, Switzerland: WHO, 2003. http://www.who.int/tb/publications/cds-tb-2003-313/en/ Accessed February 2009.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006. http://www.who.int/tb/publications/2006/who-htm-tb-2006-361/en/index.html Accessed February 2009.
11. Lan N T N, Lademarco M F, Binkin N J, Tung L B, Quy H T, Cĵ N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001; 5: 575-578.
12. Farmer P, Kim J Y. Community based approaches to the control of multidrug resistant tuberculosis: introducing 'DOTS-plus'. BMJ 1998; 317: 671-674.
13. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
14. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312.
15. Heldal E, Arnadottir T, Cruz J R, Tardencilla A, Chacon L. Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients. Int J Tuberc Lung Dis 2001; 5: 129-136.
16. Department of Health of South Africa. The South African Tuberculosis Control Programme: practical guidelines. Pretoria, South Africa: Department of Health of South Africa, 2004. http://www.kznhealth.gov.za/chrp/documents/ Guidelines/Guidelines%20National/Tuberculosis/SA%20TB%20Guidelines%202004.pdf Accessed February 2009.
17. Dorman S E, Chaisson R E. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007; 13: 295-298.
18. Salaniponi F M, Nyirenda T E, Kemp J R, Squire S B, Godfrey-Faussett P, Harries A D. Characteristics, management and outcome of patients with recurrent tuberculosis under routine programme conditions in Malawi. Int J Tuberc Lung Dis 2003; 7: 948-952. (Pubitemid 37237057)
19. Affolabi D, Adjagba O A, Tanimomo-Kledjo B, Gninafon M, Anagonou S Y, Portaels F. Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis 2007; 11: 1221-1224. (Pubitemid 350146304)
20. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430. (Pubitemid 16126276)
21. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
22. Espinal M A. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003; 7: 607-608.
23. Caminero J A. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.
24. Saravia J C, Appleton S C, Rich M L, Sarria M, Bayona J, Becerra M C. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-429. (Pubitemid 40524034)